Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAF Switching in CHB Patients with Suboptimal Response or Intolerance to Entecavir
NCT04034368Phase 4Unknown
- Sponsor
- The First Hospital of Jilin University
- Start
- Aug 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of tenofovir alafenamide in Chronic Hepatitis B (CHB), sponsored by The First Hospital of Jilin University. Status: unknown.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04034368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04034368.